You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm is offering approximately 3 million shares and said it may use a portion of the proceeds to acquire, license, or invest in complementary businesses or products.
The synthetic biology firm had total revenues of $19.3 million and withdrew its financial guidance for fiscal year 2020 citing uncertainty caused by COVID-19.
The Cambridge, UK-based gene synthesis firm plans to use the funds to accelerate development of its silicon platform and introduce a desktop device.
The offering of common stock will be the second for Twist this year and the third since the company made its initial public offering in October 2018.
The company booked a net loss of $55.6 million, or $1.69 per share, for the quarter which included litigation settlement expenses of $22.5 million.
A hearing scheduled for Friday, part of a lawsuit filed by Agilent was cancelled, leading to speculation the sides were close to a settlement.
Illumina, Twist Bioscience, and DNA Script are among the private sector collaborators of the groups receiving funds to develop technology platforms.
The firm said it plans to sign between five and 10 additional biopharma collaborations in fiscal year 2020, some with milestone and royalty payment structures.
The firm reported full year revenues of $54.4 million and fiscal Q4 revenues of $15.7 million, beating the consensus Wall Street estimates for both.
LGC provides customers across multiple markets with reference materials, proficiency testing, oligonucleotides, genomics reagents, and instrumentation.
The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.
The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.
The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.
In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.